Advertisement
GNPX vs OMER
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNPX is a StrongBuy and OMER is a StrongBuy.
GNPX's RSI Oscillator is sitting in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in 148 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
GNPX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GNPX as a result. In 68 of 70 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GNPX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.110) is normal, around the industry mean (2.973). P/E Ratio (0.058) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. GNPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
OMER's RSI Indicator ascends from oversold territory
The RSI Indicator for OMER moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 25 of the 28 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMER advanced for three days, in 220 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
OMER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OMER as a result. In 67 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for OMER turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 39 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
OMER moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OMER crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for OMER entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-22.922) is normal, around the industry mean (2.988). P/E Ratio (8.469) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (35.714) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. OMER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OMER’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
GNPX | OMER | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 89 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 97 | |
SMR RATING 1..100 | 100 | 11 | |
PRICE GROWTH RATING 1..100 | 97 | 36 | |
P/E GROWTH RATING 1..100 | 96 | 74 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OMER's Valuation (9) in the Biotechnology industry is somewhat better than the same rating for GNPX (52) in the Pharmaceuticals Major industry. This means that OMER’s stock grew somewhat faster than GNPX’s over the last 12 months.
OMER's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as GNPX (100) in the Pharmaceuticals Major industry. This means that OMER’s stock grew similarly to GNPX’s over the last 12 months.
OMER's SMR Rating (11) in the Biotechnology industry is significantly better than the same rating for GNPX (100) in the Pharmaceuticals Major industry. This means that OMER’s stock grew significantly faster than GNPX’s over the last 12 months.
OMER's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for GNPX (97) in the Pharmaceuticals Major industry. This means that OMER’s stock grew somewhat faster than GNPX’s over the last 12 months.
OMER's P/E Growth Rating (74) in the Biotechnology industry is in the same range as GNPX (96) in the Pharmaceuticals Major industry. This means that OMER’s stock grew similarly to GNPX’s over the last 12 months.
| GNPX | OMER | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 89% | 2 days ago 89% |
| Stochastic ODDS (%) | 1 day ago 78% | 2 days ago 82% |
| Momentum ODDS (%) | 1 day ago 90% | 2 days ago 76% |
| MACD ODDS (%) | N/A | 2 days ago 90% |
| TrendWeek ODDS (%) | 1 day ago 90% | 2 days ago 84% |
| TrendMonth ODDS (%) | 1 day ago 90% | 2 days ago 86% |
| Advances ODDS (%) | 15 days ago 76% | 3 days ago 84% |
| Declines ODDS (%) | 1 day ago 90% | 9 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 84% | 2 days ago 83% |
| Aroon ODDS (%) | 1 day ago 90% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GNPX’s FA Score shows that 0 FA rating(s) are green while OMER’s FA Score has 2 green FA rating(s).
- GNPX’s FA Score: 0 green, 5 red.
- OMER’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GNPX’s TA Score shows that 4 TA indicator(s) are bullish while OMER’s TA Score has 4 bullish TA indicator(s).
- GNPX’s TA Score: 4 bullish, 3 bearish.
- OMER’s TA Score: 4 bullish, 6 bearish.
Price Growth
GNPX (@Biotechnology) experienced а -12.02% price change this week, while OMER (@Biotechnology) price change was -11.77% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
GNPX is expected to report earnings on Nov 13, 2026.
OMER is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
GNPX and
Correlation & Price change
A.I.dvisor indicates that over the last year, GNPX has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if GNPX jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To GNPX | 1D Price Change % | ||
|---|---|---|---|---|
| GNPX | 100% | -3.41% | ||
| CANF - GNPX | 93% Closely correlated | -3.15% | ||
| APVO - GNPX | 86% Closely correlated | +0.62% | ||
| ICU - GNPX | 82% Closely correlated | -10.09% | ||
| MLEC - GNPX | 76% Closely correlated | +1.51% | ||
| LONA - GNPX | 76% Closely correlated | -12.35% | ||
More | ||||
OMER and
Correlation & Price change
A.I.dvisor indicates that over the last year, OMER has been loosely correlated with GNPX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if OMER jumps, then GNPX could also see price increases.
| Ticker / NAME | Correlation To OMER | 1D Price Change % | ||
|---|---|---|---|---|
| OMER | 100% | -1.75% | ||
| GNPX - OMER | 51% Loosely correlated | -3.76% | ||
| VCYT - OMER | 40% Loosely correlated | +3.19% | ||
| INM - OMER | 36% Loosely correlated | +2.99% | ||
| TOVX - OMER | 35% Loosely correlated | -5.48% | ||
| ABSI - OMER | 34% Loosely correlated | +10.69% | ||
More | ||||